Kubitz R, Bode J, Erhardt A, Graf D, Kircheis G, Müller-Stöver I, Reinehr R, Reuter S, Richter J, Sagir A, Schmitt M, Donner M
Klinik für Gastroenterologie, Hepatologie und Infektiologie, Universitätsklinikum Düsseldorf.
Z Gastroenterol. 2011 Jun;49(6):728-36. doi: 10.1055/s-0031-1273427. Epub 2011 Jun 1.
The phospholipidfloppase MDR3 (gene symbol: ABCB4) is expressed in the canalicular membrane of hepatocytes and mediates the biliary excretion of phosphatidylcholine, which is required for the formation of mixed micelles in bile. Several mutations of ABCB4 have been identified, which cause cholestatic liver diseases of varying severity including progressive familial intrahepatic cholestasis type 3 (PFIC-3), intrahepatic cholestasis of pregnancy (ICP) and the low phospholipid associated cholelithiasis syndrome (LPAC). Here, we report on four new (S1076N; L 23Hfs16X; c.286 + 1G > A; Q 1181E) and one known (S27G) MDR3 mutations in eight patients of three families. The patients presented with a wide spectrum of liver diseases. The clinical presentation and decisive laboratory findings or the association to a trend-setting family history led to the identification of the genetic background in these patients. Even the same mutation may be associated with varying disease progression.
磷脂翻转酶MDR3(基因符号:ABCB4)在肝细胞的胆小管膜中表达,并介导磷脂酰胆碱的胆汁排泄,而磷脂酰胆碱是胆汁中混合微团形成所必需的。已鉴定出ABCB4的几种突变,这些突变会导致不同严重程度的胆汁淤积性肝病,包括3型进行性家族性肝内胆汁淤积症(PFIC-3)、妊娠期肝内胆汁淤积症(ICP)和低磷脂相关胆石症综合征(LPAC)。在此,我们报告了三个家族的八名患者中四个新的(S1076N;L23Hfs16X;c.286+1G>A;Q1181E)和一个已知的(S27G)MDR3突变。这些患者表现出广泛的肝脏疾病。临床表现、决定性的实验室检查结果或与典型家族病史的关联导致了这些患者遗传背景的确定。即使是相同的突变也可能与不同的疾病进展相关。